EAU 2017 | Is it possible to destroy the cancer while preserving the prostate?
Mark Emberton, MD, FRCS Urol, from University College London Hospitals NHS Foundation Trust, London, UK, discusses the potential of intraprostatic PRX302 injection for prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the advantages of imaging technologies to visualize the tumor, and speaks about how this allows localized treatment to be carried out and what this means for the patient. Prof. Emberton describes different approaches for targeting the tumor, including energy sources and pharmaceutical approaches, and outlines how the effects of the bacterial toxin PRX302 can be limited to the prostate. He speaks about safety results from a Phase I trial of PRX302 (NCT00379561), and the ongoing Phase IIa trial (NCT02499848).
Get great new content delivered to your inboxSign up